text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 129-06-6 | Product Number: W0005

Warfarin Sodium (contains Isopropyl Alcohol)


Purity: >98.0%(HPLC)
Synonyms:
  • 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
  • 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
Documents:
5G
¥525.00
1   1   ≥20 
25G
¥1,580.00
5   1   3  

* For order or inquiry, please contact Our Authorized Distributors.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.


Product Number W0005
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__1__9H__1__5NaO__4 = 330.31  
Physical State (20 deg.C) Solid
Store Under Inert Gas Store under inert gas
Condition to Avoid Air Sensitive
CAS RN 129-06-6
Related CAS RN 81-81-2
Reaxys Registry Number 5469050
PubChem Substance ID 87560363
Merck Index (14) 10038
MDL Number

MFCD00083223

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 91.0 %
2-Propanol 7.0 to 9.0 %
Properties (reference)
Solubility in water Completely soluble
Solubility (very soluble in) Alcohol
Solubility (slightly sol. in) Ether,Chloroform
GHS
Pictogram Pictogram Pictogram
Signal Word Danger
Hazard Statements H300 : Fatal if swallowed.
H360 : May damage fertility or the unborn child.
H370 : Causes damage to organs.
H372 : Causes damage to organs through prolonged or repeated exposure.
H373 : May cause damage to organs through prolonged or repeated exposure.
H412 : Harmful to aquatic life with long lasting effects.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P273 : Avoid release to the environment.
P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.
P270 : Do not eat, drink or smoke when using this product.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor.
P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.
P405 : Store locked up.
Related Laws:
RTECS# GN4725000
Transport Information:
UN Number UN1544
Class 6.1
Packing Group II
Customs Control Conditions (Q)
Application
Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin

Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.
【SPR】
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.

W0005

<Assay condition>
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.

<Result>
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
【Method using fluorescent probes】
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.

W0005

<Assay condition>
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).

<Result>
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
In these ways, our warfarin can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.

References


Application
Reviews of Pharmacology of Warfarin

References


PubMed Literature


TCIMAIL
Documents
Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents